-
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by
prnasia
March 02, 2021
INOVIO today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial.
-
NHS England to trial at-home smear testing kits
pharmatimes
February 25, 2021
NHS England has announced a trial which will see over 31,000 women offered at-home smear testing kits in a bid to combat low attendance for the ‘life-saving’ screenings.
-
INOVIO Receives Orphan Drug Designation for Recurrent Respiratory papillomatosis Treatment
americanpharmaceuticalreview
August 05, 2020
INOVIO announced the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP).
-
BD Receives FDA Approval for HPV Test with Extended Genotyping Capabilities
americanpharmaceuticalreview
July 29, 2020
BD has received approval for a pre-market approval (PMA) supplement from the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity™ HPV Assay.
-
US expands scope of MSD's Gardasil
pharmatimes
June 16, 2020
MSD has bagged US approval for an expanded indication for Gardasil for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.
-
Mortality Risk in Oropharynx Cancer Varies Based on HPV Status
drugs
January 20, 2020
For patients with oropharynx cancer, the rates of head and neck cancer (HNC) mortality and competing mortality vary depending on human papillomavirus (HPV) status, with increased risks for HNC mortality and competing mortality in HPV-negative patients ...
-
Young Adults Who Ever Received HPV Vaccine on the Rise
drugs
January 20, 2020
From 2013 to 2018, there was an increase in the percentage of adults aged 18 to 26 years who received one or more doses or the recommended number of doses of human papillomavirus (HPV) vaccine ...
-
Routine HPV Testing May Be Warranted for Sinonasal Cancers
drugs
January 06, 2020
Only one in four patients with sinonasal squamous cell carcinoma (SNSCC) is tested for human papillomavirus (HPV), according to a study published online December in Cancer.
-
Could One Dose of HPV Vaccine Be Enough?
drugs
December 30, 2019
In a finding that might make the HPV vaccine more palatable to many, new research suggests a single dose may provide just as much protection from cervical cancer as the recommended two to three doses do.
-
Protection Similar With Single, Multiple HPV Vaccine Doses
drugs
December 30, 2019
U.S. women who have received one dose of human papillomavirus (HPV) vaccine have similar protection as women who have received two or three doses ...